Chris Varma is founder, president and CEO of Blueprint Medicines. He has also been entrepreneur-in-residence at Third Rock Ventures since 2010, bringing with him experience as an entrepreneur and an investor in the pharmaceutical and biotechnology industries. Previously, Varma was a partner at Flagship Ventures, where he also served as the president, CEO and director of Selventa (formerly Genstruct, Inc.), a Flagship portfolio company. He previously oversaw efforts spanning clinical development, business development, and sales and marketing at Novartis AG. Most recently, Varma was director on Tekturna (aliskiren). Prior to Novartis, he was a consultant for Millennium Pharmaceuticals, and before that worked for the U.S. Food and Drug Administration. Varma holds a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences & Technology, an M.S. in management from Stanford University, and both an M.S. and B.S. in computer science from Stanford.

Panels:
Financial Innovations for Early-Stage Drug Development

The Human Genome: A User's Guide

Tweet